1. The State Council The People’s Republic of China.http://www.gov.cn/zhengce/content/2015‐08/18/content_10101.htm. Accessed September 19 2020.
2. National Medical Products Administration.Technical guideline of new drug Phase I clinical study application.http://www.cde.org.cn/zdyz.do?method=largePage&id=5861485dbdae74a3(2018). Accessed September 19 2020.
3. Food and Drug Administration.Content and format of Investigational New Drug Applications (INDs) for Phase 1 studies of drugs including well‐characterized therapeutic biotechnology‐derived products.https://www.fda.gov/media/71203/download(1995). Accessed September 19 2020.
4. Food and Drug Administration.Content and format of INDs for Phase 1 studies of drugs including well‐characterized therapeutic biotechnology‐derived products. Questions and Answers.https://www.fda.gov/media/72284/download(2000). Accessed September 19 2020.
5. European Medicines Agency.Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products.https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐strategies‐identify‐mitigate‐risks‐first‐human‐early‐clinical‐trials‐investigational_en.pdf(2017). Accessed September 19 2020.